{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:46:55Z","timestamp":1793785615410,"version":"4.6.1"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"Importance<\/jats:title>Cognitive deficits are a substantial part of the symptoms of schizophrenia spectrum disorders (SSDs) and contribute heavily to the burden of disease. Antipsychotic drugs are not cognitive enhancers, but due to their different receptor-binding profiles, they could differ in their effects on cognition. No previous network meta-analysis compared antipsychotics to placebo, which is important to determine whether use of these drugs is associated with cognitive performance in SSDs at all.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine the association of treatment with various antipsychotics and cognition in patients with SSDs.<\/jats:p><\/jats:sec>Data Sources<\/jats:title>Cochrane Schizophrenia Trials Register through June 25, 2023.<\/jats:p><\/jats:sec>Study Selection<\/jats:title>Randomized clinical trials examining the effects on cognition of antipsychotic drugs or placebo in participants with SSD.<\/jats:p><\/jats:sec>Data Extraction and Synthesis<\/jats:title>A systematic review and random-effects frequentist network meta-analysis was performed following Preferred Reporting Items for Systematic Reviews and Meta-analyses\u2013Network Meta-analysis reporting guideline.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was change in overall cognition score calculated for each study. Secondary outcomes included cognitive domains, quality of life, and functioning.<\/jats:p><\/jats:sec>Results<\/jats:title>This study included 68 studies involving 9525 participants (mean [SD] age, 35.1 [8.9] years; 5878 male [70%] and 2890 [30%] female; some studies did not provide this information). There were few clear differences between antipsychotics, but first-generation dopamine antagonists haloperidol (standardized mean difference [SMD], 0.04; 95% CI, \u22120.25 to 0.33) and fluphenazine (SMD, 0.15; 95% CI, \u22120.39 to 0.69) as well as clozapine (SMD, 0.12; 95% CI, \u22120.23 to 0.48) ranked low. No individual antipsychotic was associated with a clearly better outcome than placebo, but antipsychotics as a group were, with small effect sizes (mean SMDs: adrenergic\/low dopamine, \u22120.21; serotonergic\/dopaminergic, \u22120.26; muscarinic, \u22120.28; dopaminergic, \u22120.40).<\/jats:p><\/jats:sec>Conclusion and Relevance<\/jats:title>Although data are relatively sparse, those reviewed in this study suggest that first-generation dopamine antagonists and clozapine should be avoided when cognitive deficits are a concern. Antipsychotics are not procognitive drugs. The overall small superior outcomes compared to placebo may be explained by less disordered thought patterns associated with fewer positive symptoms rather than cognitive deficits in the proper sense. The findings also suggest that harmonizing measurement of cognitive function in randomized clinical trials would be beneficial.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2024.2890","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T15:00:50Z","timestamp":1729090850000},"page":"47","source":"Crossref","is-referenced-by-count":114,"title":["Antipsychotic Drugs and Cognitive Function"],"prefix":"10.1001","volume":"82","author":[{"given":"Lena","family":"Feber","sequence":"first","affiliation":[{"name":"Technical University of Munich, TUM School of Medicine and Health, Klinikum rechts der Isar, Department of Psychiatry and Psychotherapy, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie L.","family":"Peter","sequence":"additional","affiliation":[{"name":"Technical University of Munich, TUM School of Medicine and Health, Klinikum rechts der Isar, Department of Psychiatry and Psychotherapy, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Chiocchia","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schneider-Thoma","sequence":"additional","affiliation":[{"name":"Technical University of Munich, TUM School of Medicine and Health, Klinikum rechts der Isar, Department of Psychiatry and Psychotherapy, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Siafis","sequence":"additional","affiliation":[{"name":"Technical University of Munich, TUM School of Medicine and Health, Klinikum rechts der Isar, Department of Psychiatry and Psychotherapy, Munich, Germany"},{"name":"German Center for Mental Health, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bighelli","sequence":"additional","affiliation":[{"name":"Technical University of Munich, TUM School of Medicine and Health, Klinikum rechts der Isar, Department of Psychiatry and Psychotherapy, Munich, Germany"},{"name":"German Center for Mental Health, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wulf-Peter","family":"Hansen","sequence":"additional","affiliation":[{"name":"B\u00fcndnis f\u00fcr psychisch erkrankte Menschen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Lin","sequence":"additional","affiliation":[{"name":"Technical University of Munich, TUM School of Medicine and Health, Klinikum rechts der Isar, Department of Psychiatry and Psychotherapy, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Prates-Baldez","sequence":"additional","affiliation":[{"name":"Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Salanti","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S. E.","family":"Keefe","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf R.","family":"Engel","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Technical University of Munich, TUM School of Medicine and Health, Klinikum rechts der Isar, Department of Psychiatry and Psychotherapy, Munich, Germany"},{"name":"German Center for Mental Health, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"yoi240062r1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/j.2051-5545.2008.tb00143.x","article-title":"Cognitive deficits in schizophrenia: short-term and long-term.","volume":"7","author":"Kane","year":"2008","journal-title":"World Psychiatry"},{"issue":"4","key":"yoi240062r2","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1093\/schbul\/sbm046","article-title":"How should DSM-V criteria for schizophrenia include cognitive impairment?","volume":"33","author":"Keefe","year":"2007","journal-title":"Schizophr Bull"},{"issue":"1-3","key":"yoi240062r3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.schres.2006.08.021","article-title":"A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects.","volume":"89","author":"Woodward","year":"2007","journal-title":"Schizophr Res"},{"issue":"3","key":"yoi240062r4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/acps.12374","article-title":"Second-generation antipsychotic effect on cognition in patients with schizophrenia\u2014a meta-analysis of randomized clinical trials.","volume":"131","author":"Nielsen","year":"2015","journal-title":"Acta Psychiatr Scand"},{"key":"yoi240062r5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.neubiorev.2021.03.028","article-title":"The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: network meta-analyses of randomized controlled trials.","volume":"126","author":"Baldez","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"yoi240062r6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00228-013-1600-y","article-title":"Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis.","volume":"70","author":"D\u00e9sam\u00e9ricq","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"yoi240062r7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13643-023-02213-5","article-title":"Antipsychotic drugs and their effects on cognitive function: protocol for a systematic review, pairwise, and network meta-analysis.","volume":"12","author":"Feber","year":"2023","journal-title":"Syst Rev"},{"issue":"1","key":"yoi240062r8","doi-asserted-by":"publisher","DOI":"10.1093\/schizbullopen\/sgaa061","article-title":"Cochrane schizophrenia group\u2019s study-based register of randomized controlled trials: development and content analysis.","volume":"1","author":"Shokraneh","year":"2020","journal-title":"Schizophr Bull Open"},{"issue":"6","key":"yoi240062r9","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing.","volume":"167","author":"Gardner","year":"2010","journal-title":"Am J Psychiatry"},{"issue":"2","key":"yoi240062r10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1176\/appi.ajp.2007.07010089","article-title":"Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.","volume":"165","author":"Green","year":"2008","journal-title":"Am J Psychiatry"},{"issue":"2","key":"yoi240062r11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1176\/appi.ajp.2007.07010043","article-title":"The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.","volume":"165","author":"Kern","year":"2008","journal-title":"Am J Psychiatry"},{"issue":"2","key":"yoi240062r12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","article-title":"The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.","volume":"165","author":"Nuechterlein","year":"2008","journal-title":"Am J Psychiatry"},{"issue":"2-3","key":"yoi240062r13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0920-9964(03)00125-7","article-title":"Impairment of verbal memory and learning in antipsychotic-na\u00efve patients with first-episode schizophrenia.","volume":"68","author":"Hill","year":"2004","journal-title":"Schizophr Res"},{"issue":"9","key":"yoi240062r14","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1038\/sj.npp.1301072","article-title":"Baseline neurocognitive deficits in the CATIE schizophrenia trial.","volume":"31","author":"Keefe","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"yoi240062r15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.schres.2004.09.007","article-title":"Identification of separable cognitive factors in schizophrenia.","volume":"72","author":"Nuechterlein","year":"2004","journal-title":"Schizophr Res"},{"issue":"2","key":"yoi240062r16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies.","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"issue":"7-8","key":"yoi240062r17","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis.","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"issue":"1","key":"yoi240062r18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods.","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"yoi240062r19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.biopsych.2023.04.004","article-title":"Data-driven taxonomy for antipsychotic medication: a new classification system.","volume":"94","author":"McCutcheon","year":"2023","journal-title":"Biol Psychiatry"},{"issue":"1","key":"yoi240062r20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000442209","article-title":"The comparative effects of risperidone long-acting injection and paliperidone palmitate on social functioning in schizophrenia: a 6-month, open-label, randomized controlled pilot trial.","volume":"73","author":"Koshikawa","year":"2016","journal-title":"Neuropsychobiology"},{"issue":"1","key":"yoi240062r21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/2045125313499065","article-title":"Comparison of the Effects of Sertindole and Olanzapine on Cognition (SEROLA): a double-blind randomized 12-week study of patients diagnosed with schizophrenia.","volume":"4","author":"Ernst Nielsen","year":"2014","journal-title":"Ther Adv Psychopharmacol"},{"issue":"3","key":"yoi240062r22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/schbul\/sbs001","article-title":"The Cognitive Assessment Interview (CAI): reliability and validity of a brief interview-based measure of cognition.","volume":"39","author":"Ventura","year":"2013","journal-title":"Schizophr Bull"},{"issue":"2","key":"yoi240062r23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.euroneuro.2014.06.009","article-title":"Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale.","volume":"25","author":"Keefe","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"yoi240062r24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0010-440X(03)00086-5","article-title":"Exploring cognitive complaints in schizophrenia: the subjective scale to investigate cognition in schizophrenia.","volume":"44","author":"Stip","year":"2003","journal-title":"Compr Psychiatry"},{"key":"yoi240062r25","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/0924-977X(96)00010-7","article-title":"Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs.","volume":"6","author":"Gallhofer","year":"1996","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"yoi240062r26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1055\/s-2007-979481","article-title":"Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study.","volume":"30","author":"Meyer-Lindenberg","year":"1997","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"yoi240062r27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1176\/ps.47.1.41","article-title":"Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning.","volume":"47","author":"Grace","year":"1996","journal-title":"Psychiatr Serv"},{"issue":"10","key":"yoi240062r28","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors.","volume":"174","author":"Leucht","year":"2017","journal-title":"Am J Psychiatry"},{"issue":"10202","key":"yoi240062r29","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1176\/appi.focus.18306","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"9896","key":"yoi240062r30","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"yoi240062r31","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1007\/s12325-021-01797-5","article-title":"Cariprazine, a broad-spectrum antipsychotic for the treatment of schizophrenia: pharmacology, efficacy, and safety.","volume":"38","author":"Laszlovszky","year":"2021","journal-title":"Adv Ther"},{"issue":"3","key":"yoi240062r32","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1017\/S109285292200013X","article-title":"The efficacy of cariprazine on cognition: a post hoc analysis from phase II\/III clinical trials in bipolar mania, bipolar depression, and schizophrenia.","volume":"28","author":"McIntyre","year":"2023","journal-title":"CNS Spectr"},{"issue":"3","key":"yoi240062r33","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s00739-022-00802-y","article-title":"Wirkungen von Cariprazin auf Negativsymptome und kognitive St\u00f6rungen bei Schizophrenie.","volume":"25","author":"Sachs","year":"2022","journal-title":"Psychopraxis Neuropraxis"},{"issue":"4","key":"yoi240062r34","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.4088\/JCP.13m08853","article-title":"Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials.","volume":"75","author":"Rabinowitz","year":"2014","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"yoi240062r35","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1176\/appi.ajp.160.2.356","article-title":"The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia.","volume":"160","author":"Carpenter","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"7","key":"yoi240062r36","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00406-023-01576-z","article-title":"Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia.","volume":"273","author":"Rosenbrock","year":"2023","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"5","key":"yoi240062r37","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1176\/appi.ajp.2010.10060855","article-title":"A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes.","volume":"168","author":"Wykes","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"12","key":"yoi240062r38","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1176\/appi.ajp.2007.07060906","article-title":"A meta-analysis of cognitive remediation in schizophrenia.","volume":"164","author":"McGurk","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"1","key":"yoi240062r39","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2022.2315","article-title":"European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia.","volume":"65","author":"Vita","year":"2022","journal-title":"Eur Psychiatry"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2825154\/jamapsychiatry_feber_2024_oi_240062_1735586213.81166.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T16:01:37Z","timestamp":1735833697000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2825154"}},"subtitle":["A Systematic Review and Network Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.2890","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}